Discovering gene expression signatures responding to tyrosine kinase inhibitor treatment in chronic myeloid leukemia

BACKGROUND: Tyrosine kinase inhibitor (TKI)-based therapy is a recommended treatment for patients with chronic myeloid leukemia (CML). However, a considerable group of CML patients do not respond well to the TKI therapy. Challenging to overcome this problem, we tried to discover molecular signatures...

Descripción completa

Detalles Bibliográficos
Autores principales: Cha, Kihoon, Li, Yi, Yi, Gwan-Su
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989900/
https://www.ncbi.nlm.nih.gov/pubmed/27534394
http://dx.doi.org/10.1186/s12920-016-0194-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989900/
https://www.ncbi.nlm.nih.gov/pubmed/27534394
http://dx.doi.org/10.1186/s12920-016-0194-5

Ejemplares similares